Concepts (344)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 1 | 24 | 2023 | 121 | 9.140 |
Why?
|
| Blood Glucose | 27 | 2023 | 300 | 4.870 |
Why?
|
| Exercise | 18 | 2023 | 451 | 3.470 |
Why?
|
| Insulin Resistance | 5 | 2022 | 165 | 2.970 |
Why?
|
| Diabetes Mellitus, Type 2 | 8 | 2023 | 321 | 2.700 |
Why?
|
| Postprandial Period | 9 | 2022 | 41 | 2.130 |
Why?
|
| Hypoglycemic Agents | 10 | 2022 | 105 | 2.130 |
Why?
|
| Insulin | 13 | 2022 | 309 | 2.080 |
Why?
|
| Thrombosis | 3 | 2022 | 147 | 2.040 |
Why?
|
| Fatty Acids, Omega-3 | 3 | 2021 | 30 | 2.030 |
Why?
|
| Hypoglycemia | 9 | 2022 | 33 | 2.000 |
Why?
|
| Insulin, Short-Acting | 4 | 2021 | 4 | 1.550 |
Why?
|
| Dietary Fats | 3 | 2022 | 55 | 1.500 |
Why?
|
| Cardiovascular Diseases | 3 | 2021 | 346 | 1.460 |
Why?
|
| Glycated Hemoglobin A | 11 | 2022 | 64 | 1.370 |
Why?
|
| Dietary Supplements | 4 | 2020 | 212 | 1.270 |
Why?
|
| Oligopeptides | 5 | 2021 | 95 | 1.250 |
Why?
|
| Diet, High-Fat | 2 | 2021 | 130 | 1.230 |
Why?
|
| Meals | 4 | 2020 | 20 | 1.200 |
Why?
|
| Humans | 53 | 2023 | 26856 | 1.180 |
Why?
|
| Mitochondria | 7 | 2023 | 325 | 1.170 |
Why?
|
| Inflammation Mediators | 4 | 2021 | 152 | 1.120 |
Why?
|
| Biomarkers | 10 | 2022 | 731 | 1.110 |
Why?
|
| Adult | 27 | 2022 | 7389 | 1.100 |
Why?
|
| Muscle, Skeletal | 6 | 2023 | 578 | 1.090 |
Why?
|
| Male | 35 | 2022 | 12866 | 1.020 |
Why?
|
| Blood Coagulation | 3 | 2021 | 116 | 0.990 |
Why?
|
| Aging | 8 | 2023 | 954 | 0.960 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 2 | 2021 | 20 | 0.940 |
Why?
|
| Dietary Carbohydrates | 4 | 2017 | 22 | 0.930 |
Why?
|
| Fibrinogen | 2 | 2021 | 50 | 0.920 |
Why?
|
| Prediabetic State | 2 | 2020 | 10 | 0.870 |
Why?
|
| Hyperglycemia | 8 | 2020 | 77 | 0.860 |
Why?
|
| Precision Medicine | 2 | 2020 | 67 | 0.800 |
Why?
|
| Diabetes Mellitus | 2 | 2023 | 207 | 0.790 |
Why?
|
| Female | 27 | 2023 | 14462 | 0.780 |
Why?
|
| Insulin Glargine | 5 | 2017 | 6 | 0.780 |
Why?
|
| Metabolic Syndrome | 2 | 2023 | 77 | 0.780 |
Why?
|
| Lipid Droplets | 1 | 2021 | 7 | 0.760 |
Why?
|
| Thromboplastin | 1 | 2021 | 28 | 0.740 |
Why?
|
| Bifidobacterium | 1 | 2020 | 2 | 0.720 |
Why?
|
| Hepatitis C | 1 | 2021 | 38 | 0.720 |
Why?
|
| Time Factors | 9 | 2021 | 1564 | 0.720 |
Why?
|
| Life Style | 2 | 2023 | 82 | 0.710 |
Why?
|
| Abdominal Pain | 1 | 2020 | 34 | 0.710 |
Why?
|
| Probiotics | 1 | 2020 | 16 | 0.710 |
Why?
|
| Irritable Bowel Syndrome | 1 | 2020 | 32 | 0.700 |
Why?
|
| Glucose | 5 | 2022 | 190 | 0.700 |
Why?
|
| Running | 3 | 2015 | 39 | 0.680 |
Why?
|
| Risk Reduction Behavior | 1 | 2020 | 40 | 0.680 |
Why?
|
| Physical Conditioning, Animal | 2 | 2018 | 34 | 0.670 |
Why?
|
| Hemodynamics | 1 | 2020 | 220 | 0.660 |
Why?
|
| Treatment Outcome | 7 | 2022 | 2267 | 0.650 |
Why?
|
| Time-to-Treatment | 1 | 2019 | 26 | 0.640 |
Why?
|
| Oxidative Stress | 3 | 2023 | 619 | 0.630 |
Why?
|
| Diabetic Angiopathies | 1 | 2018 | 47 | 0.610 |
Why?
|
| Energy Metabolism | 3 | 2020 | 176 | 0.610 |
Why?
|
| Inflammation | 3 | 2021 | 598 | 0.610 |
Why?
|
| Glycemic Index | 2 | 2014 | 5 | 0.600 |
Why?
|
| Insulin Detemir | 2 | 2017 | 2 | 0.600 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2018 | 12 | 0.600 |
Why?
|
| Microvessels | 1 | 2018 | 85 | 0.600 |
Why?
|
| Attitude of Health Personnel | 1 | 2019 | 139 | 0.600 |
Why?
|
| Exercise Tolerance | 1 | 2018 | 82 | 0.600 |
Why?
|
| Risk Factors | 7 | 2023 | 2017 | 0.590 |
Why?
|
| Long QT Syndrome | 1 | 2018 | 12 | 0.590 |
Why?
|
| Randomized Controlled Trials as Topic | 6 | 2023 | 358 | 0.590 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2018 | 28 | 0.590 |
Why?
|
| Defibrillators, Implantable | 1 | 2018 | 45 | 0.580 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2019 | 160 | 0.580 |
Why?
|
| Electrocardiography | 2 | 2019 | 391 | 0.560 |
Why?
|
| Myocytes, Cardiac | 2 | 2016 | 59 | 0.550 |
Why?
|
| England | 4 | 2021 | 34 | 0.540 |
Why?
|
| Young Adult | 9 | 2022 | 2584 | 0.540 |
Why?
|
| Heart Defects, Congenital | 1 | 2018 | 92 | 0.540 |
Why?
|
| Heart Conduction System | 1 | 2018 | 270 | 0.530 |
Why?
|
| Exercise Therapy | 2 | 2014 | 77 | 0.530 |
Why?
|
| Sarcoglycans | 1 | 2016 | 3 | 0.530 |
Why?
|
| Genes, Dominant | 1 | 2016 | 35 | 0.530 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2016 | 14 | 0.530 |
Why?
|
| Mechanotransduction, Cellular | 1 | 2016 | 23 | 0.520 |
Why?
|
| Diet, Diabetic | 2 | 2014 | 4 | 0.520 |
Why?
|
| Endothelial Progenitor Cells | 3 | 2022 | 15 | 0.520 |
Why?
|
| Mitochondria, Muscle | 1 | 2015 | 39 | 0.510 |
Why?
|
| Appetite | 4 | 2022 | 19 | 0.510 |
Why?
|
| Molecular Imaging | 1 | 2015 | 35 | 0.500 |
Why?
|
| Sharks | 1 | 2015 | 7 | 0.500 |
Why?
|
| Appetite Regulation | 1 | 2014 | 2 | 0.490 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2015 | 176 | 0.490 |
Why?
|
| Stress, Physiological | 1 | 2015 | 90 | 0.470 |
Why?
|
| Snacks | 1 | 2014 | 5 | 0.460 |
Why?
|
| Games, Recreational | 1 | 2014 | 3 | 0.460 |
Why?
|
| Animals | 18 | 2023 | 9954 | 0.440 |
Why?
|
| Mutation | 2 | 2023 | 820 | 0.440 |
Why?
|
| Cross-Sectional Studies | 3 | 2021 | 915 | 0.420 |
Why?
|
| Middle Aged | 9 | 2022 | 6825 | 0.410 |
Why?
|
| Resistance Training | 4 | 2015 | 190 | 0.400 |
Why?
|
| DNA, Mitochondrial | 2 | 2023 | 82 | 0.390 |
Why?
|
| Diabetes, Gestational | 2 | 2023 | 63 | 0.390 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2017 | 244 | 0.350 |
Why?
|
| Cross-Over Studies | 5 | 2022 | 125 | 0.340 |
Why?
|
| Mice | 11 | 2023 | 4402 | 0.310 |
Why?
|
| Protein Processing, Post-Translational | 2 | 2021 | 100 | 0.310 |
Why?
|
| Blood Pressure | 2 | 2020 | 351 | 0.300 |
Why?
|
| Blood Glucose Self-Monitoring | 3 | 2023 | 16 | 0.300 |
Why?
|
| Physical Fitness | 3 | 2017 | 61 | 0.290 |
Why?
|
| Breakfast | 2 | 2018 | 4 | 0.290 |
Why?
|
| Whey Proteins | 2 | 2018 | 11 | 0.280 |
Why?
|
| Lunch | 2 | 2018 | 8 | 0.280 |
Why?
|
| Phenotype | 2 | 2020 | 664 | 0.260 |
Why?
|
| Insulin Aspart | 2 | 2015 | 2 | 0.250 |
Why?
|
| Mice, Inbred C57BL | 5 | 2021 | 1474 | 0.240 |
Why?
|
| Prospective Studies | 2 | 2018 | 1219 | 0.240 |
Why?
|
| Adolescent | 4 | 2022 | 2960 | 0.240 |
Why?
|
| Interleukin-6 | 3 | 2015 | 190 | 0.230 |
Why?
|
| Oxidation-Reduction | 3 | 2021 | 352 | 0.230 |
Why?
|
| Lactic Acid | 2 | 2015 | 89 | 0.230 |
Why?
|
| Family Health | 1 | 2023 | 71 | 0.220 |
Why?
|
| Dietary Proteins | 1 | 2022 | 30 | 0.210 |
Why?
|
| Metformin | 1 | 2023 | 32 | 0.210 |
Why?
|
| Hyperkalemia | 1 | 2022 | 8 | 0.200 |
Why?
|
| Dinoflagellida | 1 | 2022 | 2 | 0.200 |
Why?
|
| Satiety Response | 1 | 2022 | 1 | 0.200 |
Why?
|
| Cicer | 1 | 2022 | 1 | 0.200 |
Why?
|
| Combined Modality Therapy | 4 | 2016 | 290 | 0.200 |
Why?
|
| Cardiorespiratory Fitness | 1 | 2022 | 8 | 0.200 |
Why?
|
| Oxygen Consumption | 3 | 2021 | 173 | 0.200 |
Why?
|
| Mutation Accumulation | 1 | 2021 | 1 | 0.200 |
Why?
|
| Food Handling | 1 | 2022 | 16 | 0.200 |
Why?
|
| Body Mass Index | 2 | 2021 | 384 | 0.200 |
Why?
|
| Child | 2 | 2018 | 2152 | 0.190 |
Why?
|
| Receptors, CXCR | 1 | 2021 | 1 | 0.190 |
Why?
|
| Germ-Line Mutation | 1 | 2021 | 31 | 0.190 |
Why?
|
| Injections, Subcutaneous | 1 | 2021 | 58 | 0.190 |
Why?
|
| Genome, Mitochondrial | 1 | 2021 | 16 | 0.190 |
Why?
|
| Linoleic Acids | 1 | 2021 | 2 | 0.190 |
Why?
|
| Double-Blind Method | 2 | 2020 | 399 | 0.190 |
Why?
|
| Erythrocyte Membrane | 1 | 2021 | 22 | 0.190 |
Why?
|
| DNA Replication | 1 | 2021 | 49 | 0.190 |
Why?
|
| Proteomics | 1 | 2023 | 177 | 0.190 |
Why?
|
| Triglycerides | 2 | 2023 | 116 | 0.190 |
Why?
|
| Muscle Proteins | 1 | 2021 | 50 | 0.190 |
Why?
|
| Coral Reefs | 1 | 2021 | 1 | 0.190 |
Why?
|
| Receptors, CXCR4 | 1 | 2021 | 27 | 0.190 |
Why?
|
| Particle Size | 1 | 2021 | 96 | 0.190 |
Why?
|
| Platelet Aggregation | 1 | 2021 | 43 | 0.180 |
Why?
|
| Fishes | 1 | 2021 | 31 | 0.180 |
Why?
|
| Telemedicine | 1 | 2023 | 135 | 0.180 |
Why?
|
| Cluster Analysis | 1 | 2021 | 114 | 0.180 |
Why?
|
| Retinal Pigment Epithelium | 1 | 2021 | 90 | 0.180 |
Why?
|
| Hepacivirus | 1 | 2021 | 46 | 0.180 |
Why?
|
| Insulin, Long-Acting | 3 | 2014 | 4 | 0.180 |
Why?
|
| Aged | 5 | 2023 | 5169 | 0.180 |
Why?
|
| Canada | 1 | 2020 | 58 | 0.180 |
Why?
|
| Environmental Monitoring | 1 | 2021 | 62 | 0.180 |
Why?
|
| Machine Learning | 1 | 2021 | 79 | 0.180 |
Why?
|
| Mitochondria, Heart | 1 | 2020 | 23 | 0.180 |
Why?
|
| Glucose Intolerance | 1 | 2020 | 22 | 0.170 |
Why?
|
| Adenosine Triphosphate | 2 | 2021 | 115 | 0.170 |
Why?
|
| Heart Diseases | 1 | 2020 | 68 | 0.170 |
Why?
|
| Lipids | 2 | 2018 | 195 | 0.170 |
Why?
|
| Fatty Acids | 1 | 2021 | 198 | 0.170 |
Why?
|
| Retrospective Studies | 3 | 2023 | 2444 | 0.170 |
Why?
|
| Vasodilation | 1 | 2020 | 114 | 0.170 |
Why?
|
| Collagen Type IV | 2 | 2017 | 6 | 0.170 |
Why?
|
| Europe, Eastern | 1 | 2019 | 1 | 0.160 |
Why?
|
| Croatia | 1 | 2019 | 1 | 0.160 |
Why?
|
| Slovenia | 1 | 2019 | 1 | 0.160 |
Why?
|
| Bulgaria | 1 | 2019 | 2 | 0.160 |
Why?
|
| Hungary | 1 | 2019 | 5 | 0.160 |
Why?
|
| Greece | 1 | 2019 | 3 | 0.160 |
Why?
|
| Drug Overdose | 1 | 2019 | 10 | 0.160 |
Why?
|
| Bradycardia | 1 | 2019 | 17 | 0.160 |
Why?
|
| Oxidative Phosphorylation | 1 | 2018 | 24 | 0.160 |
Why?
|
| Marijuana Smoking | 1 | 2019 | 31 | 0.160 |
Why?
|
| Finland | 1 | 2018 | 3 | 0.160 |
Why?
|
| Cytokines | 2 | 2018 | 437 | 0.160 |
Why?
|
| Risk Assessment | 1 | 2021 | 586 | 0.160 |
Why?
|
| Glutathione | 1 | 2018 | 68 | 0.160 |
Why?
|
| Adolescent Behavior | 1 | 2019 | 67 | 0.160 |
Why?
|
| Protective Factors | 1 | 2018 | 16 | 0.160 |
Why?
|
| Mitochondrial Proteins | 1 | 2018 | 70 | 0.150 |
Why?
|
| Guideline Adherence | 1 | 2019 | 91 | 0.150 |
Why?
|
| British Columbia | 1 | 2018 | 6 | 0.150 |
Why?
|
| Physical Endurance | 1 | 2018 | 86 | 0.150 |
Why?
|
| Germany | 1 | 2018 | 24 | 0.150 |
Why?
|
| Geriatric Assessment | 1 | 2018 | 86 | 0.150 |
Why?
|
| Retina | 1 | 2021 | 421 | 0.150 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2016 | 537 | 0.150 |
Why?
|
| Drug Therapy, Combination | 2 | 2015 | 203 | 0.140 |
Why?
|
| Decision Making | 1 | 2019 | 169 | 0.140 |
Why?
|
| Patient Selection | 1 | 2018 | 143 | 0.140 |
Why?
|
| Quality of Life | 1 | 2021 | 463 | 0.140 |
Why?
|
| Kidney Glomerulus | 1 | 2017 | 15 | 0.140 |
Why?
|
| Walking | 1 | 2018 | 130 | 0.140 |
Why?
|
| Diabetic Retinopathy | 1 | 2018 | 108 | 0.140 |
Why?
|
| Poly ADP Ribosylation | 1 | 2016 | 2 | 0.140 |
Why?
|
| Muscular Dystrophies | 1 | 2016 | 4 | 0.140 |
Why?
|
| Survival Rate | 1 | 2018 | 407 | 0.140 |
Why?
|
| Lipid Metabolism | 2 | 2015 | 118 | 0.140 |
Why?
|
| Muscle Strength | 1 | 2018 | 214 | 0.140 |
Why?
|
| Faecalibacterium | 1 | 2016 | 3 | 0.130 |
Why?
|
| Dysbiosis | 1 | 2016 | 15 | 0.130 |
Why?
|
| Predictive Value of Tests | 1 | 2018 | 472 | 0.130 |
Why?
|
| Bacteroides | 1 | 2016 | 15 | 0.130 |
Why?
|
| Clostridiales | 1 | 2016 | 6 | 0.130 |
Why?
|
| Age Factors | 1 | 2018 | 716 | 0.130 |
Why?
|
| NAD | 1 | 2016 | 81 | 0.130 |
Why?
|
| Basement Membrane | 1 | 2016 | 6 | 0.130 |
Why?
|
| Laminin | 1 | 2016 | 21 | 0.130 |
Why?
|
| Myocardial Contraction | 1 | 2016 | 60 | 0.130 |
Why?
|
| Incidence | 1 | 2018 | 545 | 0.130 |
Why?
|
| Glycosylation | 1 | 2016 | 69 | 0.130 |
Why?
|
| Cell Membrane Permeability | 1 | 2016 | 42 | 0.130 |
Why?
|
| Endothelial Cells | 2 | 2017 | 333 | 0.130 |
Why?
|
| Drug Dosage Calculations | 1 | 2015 | 4 | 0.130 |
Why?
|
| Hordeum | 1 | 2015 | 1 | 0.130 |
Why?
|
| Stress, Mechanical | 1 | 2016 | 102 | 0.130 |
Why?
|
| Protein Transport | 1 | 2016 | 152 | 0.130 |
Why?
|
| Osmolar Concentration | 1 | 2015 | 25 | 0.130 |
Why?
|
| Myocardial Ischemia | 1 | 2016 | 73 | 0.120 |
Why?
|
| Surveys and Questionnaires | 1 | 2019 | 917 | 0.120 |
Why?
|
| Transfection | 1 | 2016 | 312 | 0.120 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 981 | 0.120 |
Why?
|
| Jogging | 1 | 2014 | 2 | 0.120 |
Why?
|
| Glucagon | 1 | 2014 | 11 | 0.120 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 2014 | 5 | 0.120 |
Why?
|
| Dietary Fiber | 1 | 2014 | 6 | 0.120 |
Why?
|
| Membrane Glycoproteins | 1 | 2016 | 143 | 0.120 |
Why?
|
| Cell Membrane | 1 | 2016 | 235 | 0.120 |
Why?
|
| Calcium, Dietary | 1 | 2014 | 11 | 0.120 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2016 | 121 | 0.120 |
Why?
|
| Child, Preschool | 1 | 2018 | 1090 | 0.120 |
Why?
|
| Carbohydrate Metabolism | 1 | 2014 | 28 | 0.110 |
Why?
|
| Random Allocation | 1 | 2014 | 148 | 0.110 |
Why?
|
| Rest | 1 | 2014 | 93 | 0.110 |
Why?
|
| Cells, Cultured | 1 | 2016 | 969 | 0.110 |
Why?
|
| Oviparity | 1 | 2013 | 1 | 0.110 |
Why?
|
| Up-Regulation | 1 | 2014 | 239 | 0.110 |
Why?
|
| Heart Failure | 1 | 2016 | 232 | 0.110 |
Why?
|
| Exercise Test | 1 | 2014 | 246 | 0.110 |
Why?
|
| Calcium | 1 | 2014 | 231 | 0.110 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2013 | 24 | 0.100 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2016 | 664 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2014 | 588 | 0.100 |
Why?
|
| Sleep | 1 | 2013 | 100 | 0.100 |
Why?
|
| Reproduction | 1 | 2013 | 63 | 0.100 |
Why?
|
| Endothelium, Vascular | 1 | 2015 | 305 | 0.100 |
Why?
|
| United States | 1 | 2018 | 2035 | 0.100 |
Why?
|
| Diet | 2 | 2023 | 222 | 0.090 |
Why?
|
| Heart Rate | 2 | 2021 | 374 | 0.080 |
Why?
|
| Ecosystem | 2 | 2022 | 205 | 0.080 |
Why?
|
| Pregnancy | 2 | 2023 | 1130 | 0.080 |
Why?
|
| Pilot Projects | 2 | 2021 | 391 | 0.070 |
Why?
|
| Risk | 2 | 2016 | 133 | 0.060 |
Why?
|
| Norepinephrine | 2 | 2015 | 32 | 0.060 |
Why?
|
| Epinephrine | 2 | 2015 | 36 | 0.060 |
Why?
|
| Gene Expression Profiling | 2 | 2016 | 437 | 0.060 |
Why?
|
| Electron Transport Complex I | 1 | 2023 | 13 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2016 | 860 | 0.050 |
Why?
|
| Postmenopause | 1 | 2023 | 83 | 0.050 |
Why?
|
| Potassium | 1 | 2022 | 41 | 0.050 |
Why?
|
| Harmful Algal Bloom | 1 | 2022 | 7 | 0.050 |
Why?
|
| Florida | 1 | 2022 | 54 | 0.050 |
Why?
|
| DNA Polymerase gamma | 1 | 2021 | 1 | 0.050 |
Why?
|
| Flicker Fusion | 1 | 2021 | 1 | 0.050 |
Why?
|
| Color Vision | 1 | 2021 | 3 | 0.050 |
Why?
|
| Mutation Rate | 1 | 2021 | 5 | 0.050 |
Why?
|
| Night Vision | 1 | 2021 | 7 | 0.050 |
Why?
|
| Genetic Speciation | 1 | 2021 | 11 | 0.050 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2021 | 29 | 0.050 |
Why?
|
| Glutamine | 1 | 2021 | 32 | 0.050 |
Why?
|
| Photic Stimulation | 1 | 2021 | 67 | 0.050 |
Why?
|
| Chromosome Mapping | 1 | 2021 | 131 | 0.050 |
Why?
|
| Bicycling | 1 | 2021 | 36 | 0.050 |
Why?
|
| Administration, Oral | 1 | 2021 | 166 | 0.050 |
Why?
|
| Gulf of Mexico | 1 | 2021 | 2 | 0.050 |
Why?
|
| Animal Distribution | 1 | 2021 | 8 | 0.050 |
Why?
|
| Water | 1 | 2022 | 131 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2021 | 55 | 0.050 |
Why?
|
| Hypoxia | 1 | 2022 | 85 | 0.050 |
Why?
|
| Population Density | 1 | 2021 | 21 | 0.050 |
Why?
|
| Body Size | 1 | 2021 | 30 | 0.050 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2021 | 106 | 0.050 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2021 | 58 | 0.050 |
Why?
|
| Light | 1 | 2021 | 117 | 0.050 |
Why?
|
| Emergency Service, Hospital | 1 | 2022 | 119 | 0.050 |
Why?
|
| Electroretinography | 1 | 2021 | 173 | 0.050 |
Why?
|
| Metabolomics | 1 | 2021 | 79 | 0.050 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2020 | 29 | 0.040 |
Why?
|
| Biodiversity | 1 | 2021 | 99 | 0.040 |
Why?
|
| Heart | 1 | 2021 | 219 | 0.040 |
Why?
|
| Models, Chemical | 1 | 2020 | 88 | 0.040 |
Why?
|
| Marijuana Abuse | 1 | 2019 | 14 | 0.040 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2021 | 544 | 0.040 |
Why?
|
| Xanthophylls | 1 | 2018 | 2 | 0.040 |
Why?
|
| Protein Binding | 1 | 2020 | 631 | 0.040 |
Why?
|
| Single-Blind Method | 1 | 2018 | 43 | 0.040 |
Why?
|
| Desmin | 1 | 2017 | 1 | 0.040 |
Why?
|
| Sclerosis | 1 | 2017 | 3 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2017 | 23 | 0.040 |
Why?
|
| Podocytes | 1 | 2017 | 10 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2017 | 22 | 0.030 |
Why?
|
| Obesity | 1 | 2023 | 647 | 0.030 |
Why?
|
| Nicotinamide Phosphoribosyltransferase | 1 | 2016 | 3 | 0.030 |
Why?
|
| Tyramine | 1 | 2016 | 3 | 0.030 |
Why?
|
| Nitrosamines | 1 | 2016 | 5 | 0.030 |
Why?
|
| Adenosine Diphosphate | 1 | 2016 | 27 | 0.030 |
Why?
|
| Microfilament Proteins | 1 | 2017 | 28 | 0.030 |
Why?
|
| Muscular Diseases | 1 | 2016 | 12 | 0.030 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2017 | 80 | 0.030 |
Why?
|
| Actins | 1 | 2017 | 93 | 0.030 |
Why?
|
| Caenorhabditis elegans | 1 | 2016 | 58 | 0.030 |
Why?
|
| Fibrosis | 1 | 2016 | 115 | 0.030 |
Why?
|
| Primary Cell Culture | 1 | 2016 | 29 | 0.030 |
Why?
|
| Healthy Volunteers | 1 | 2016 | 43 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2017 | 453 | 0.030 |
Why?
|
| United Kingdom | 1 | 2015 | 70 | 0.030 |
Why?
|
| Feces | 1 | 2016 | 107 | 0.030 |
Why?
|
| Drug Monitoring | 1 | 2015 | 34 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2015 | 218 | 0.030 |
Why?
|
| Epithelial Cells | 1 | 2017 | 239 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2016 | 487 | 0.030 |
Why?
|
| Myocardium | 1 | 2016 | 171 | 0.030 |
Why?
|
| Cell Line | 1 | 2016 | 671 | 0.030 |
Why?
|
| Growth Hormone | 1 | 2015 | 103 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2016 | 645 | 0.030 |
Why?
|
| Human Growth Hormone | 1 | 2014 | 14 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2015 | 282 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2016 | 701 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2018 | 802 | 0.030 |
Why?
|
| Phylogeny | 1 | 2016 | 461 | 0.030 |
Why?
|
| Hydrocortisone | 1 | 2014 | 88 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2018 | 1927 | 0.030 |
Why?
|
| Maine | 1 | 2013 | 1 | 0.030 |
Why?
|
| Oceans and Seas | 1 | 2013 | 6 | 0.030 |
Why?
|
| Radioimmunoassay | 1 | 2013 | 45 | 0.030 |
Why?
|
| Seasons | 1 | 2013 | 83 | 0.030 |
Why?
|
| Rats | 1 | 2016 | 1536 | 0.030 |
Why?
|
| Gene Expression Regulation | 1 | 2016 | 624 | 0.030 |
Why?
|
| Progesterone | 1 | 2013 | 128 | 0.020 |
Why?
|
| Estradiol | 1 | 2013 | 174 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2013 | 388 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2016 | 1394 | 0.020 |
Why?
|